白细胞介素-6水平预测儿童急性髓系白血病无事件生存并提示化疗耐药机制
研究检测45例儿童急性髓系白血病(AML)患者和7例健康同胞对照诊断时骨髓血浆中40余种细胞因子,发现仅白细胞介素-6(IL-6)水平与无事件生存相关;在低危组中,低IL-6者5年无事件生存为82.5%±11%(n=14),高IL-6者为17.3%±11%(n=13,log-rank P=.0003);体外实验显示外源性IL-6减少米托蒽醌诱导的细胞凋亡。
要点
- 诊断时骨髓血浆IL-6水平与儿童AML无事件生存相关,高IL-6者预后差。
- 在按现行算法判为低危的患儿中,低IL-6者5年无事件生存82.5%±11%,高IL-6者17.3%±11%(P=.0003)。
- 体外外源性IL-6减少米托蒽醌诱导的细胞系和原代儿童AML样本凋亡。
核心结论
- 诊断时IL-6水平可能有助于识别高复发风险的儿童,尤其是按现行算法归为低危者。
- IL-6通路可能成为克服微环境介导化疗耐药的靶点。
研究设计与样本
- 研究检测45例儿童AML患者诊断时骨髓穿刺血浆和7例健康同胞对照血浆中40余种细胞因子和生长因子。
- 体外实验使用细胞系和原代儿童AML样本评估外源性IL-6对米托蒽醌诱导凋亡的影响。
主要发现
- 在检测的细胞因子中,仅IL-6水平与无事件生存相关。
- 在按现行算法判为低危的患儿中,诊断时低IL-6者(n=14)5年无事件生存为82.5%±11%,高IL-6者(n=13)为17.3%±11%(log-rank P=.0003)。
- 体外外源性IL-6减少米托蒽醌诱导的细胞系和原代儿童AML样本凋亡。
关键数值与推荐
- 低危组低IL-6者5年无事件生存82.5%±11%(n=14),高IL-6者17.3%±11%(n=13),log-rank P=.0003。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The tumor microenvironment can protect cancer cells from conventional anticancer therapies. Thus, targeting these protective mechanisms could eradicate therapy-resistant cancer cells and improve outcomes. Interleukin-6 (IL-6) provides extrinsic protection for several solid tumors and multiple myeloma. In pediatric acute myeloid leukemia (AML), IL-6-induced STAT3 signaling frequently becomes stronger at relapse, and increases in IL-6-induced STAT3 activity are associated with inferior survival after relapse. These findings suggested that the IL-6-induced STAT3 pathway may promote chemotherapy resistance and disease progression. Thus, we investigated the dysregulation of IL-6 levels in the bone marrow niche in pediatric patients with AML and the association between IL-6 levels and outcome. We measured levels of over 40 cytokines and growth factors in plasma from diagnostic bone marrow aspirates of 45 pediatric AML patients and 7 healthy sibling controls. Of the measured cytokines, only IL-6 levels were associated with event-free survival. Importantly, the effect of elevated IL-6 was most striking among children classified as having a low risk of relapse. In these patients, 5-year event-free survival was 82.5% ± 11% for patients with low IL-6 levels at diagnosis (n = 14) compared with 17.3% ± 11% for patients with elevated IL-6 (n = 13, log-rank P = .0003). In vitro, exogenous IL-6 reduced mitoxantrone-induced apoptosis in cell lines and primary pediatric AML samples. These results suggest that IL-6 levels at diagnosis could be used to help identify children at high risk of relapse, particularly those who are otherwise classified as low risk by current algorithms. Moreover, the IL-6 pathway could represent a target for overcoming environment-mediated chemotherapy resistance.
引用
- Stevens AM, Miller JM, Munoz JO, et al. Interleukin-6 levels predict event-free survival in pediatric AML and suggest a mechanism of chemotherapy resistance. Blood Adv. 2017. PMID: 29296780. doi:10.1182/bloodadvances.2017007856
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。